This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07395687 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 333 participants |
| Design | Interventional, Randomized, Placebo-controlled, three parts |
| Conditions | Overweight; Obesity |
| Interventions | UBT251; Placebo |
| Start | Feb 2, 2026 |
| Primary completion | Jan 14, 2027 |
| Study completion | Feb 18, 2027 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Novo Nordisk phase 2 study in three parts (A, B and C) testing whether UBT251 is safe and effective in people with overweight or obesity. Part C compares Japanese, Chinese and non-Asian participants. Participants receive UBT251 or placebo by chance.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Part A: number of treatment-emergent adverse events | Week 0 to week 33 |
| Part B: relative change in body weight | Week 0 to week 28 |
| Part C: area under the UBT251 plasma concentration-time curve | Day 1 to day 43 |
9 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Injection Phase II Clinical Study (CKD) (Phase 2 NCT07134335)
- UBT251 Injection Phase II Study (Overweight or Obesity) (Phase 2 NCT07177469)
- A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the (Phase 1 NCT07710729)
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood (Phase 1 NCT07710768)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
